Latigo Biotherapeutics (NASDAQ:LTGO) Shares Gap Up – What’s Next?

Shares of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) gapped up before the market opened on Monday . The stock had previously closed at $21.40, but opened at $22.62. Latigo Biotherapeutics shares last traded at $22.32, with a volume of 2,557 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th.

Latigo Biotherapeutics Price Performance

Insider Buying and Selling

In related news, major shareholder Foresite Capital Management V, acquired 140,000 shares of the stock in a transaction on Monday, August 10th. The stock was bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the insider directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director James B. Tananbaum purchased 140,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.